Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study | Zendy

Dongni Xu | Zendy; Jiangling Wang | Zendy; Ting Liu | Zendy; Zhuoshan Huang | Zendy; Jianwei Luo | Zendy; Yuqing Chen | Zendy; Yanan Lu | Zendy

Open Access

Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study

Author(s) -

Dongni Xu,

Jiangling Wang,

Ting Liu,

Zhuoshan Huang,

Jianwei Luo,

Yuqing Chen,

Yanan Lu

Publication year - 2021

Publication title -

gland surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.643

H-Index - 22

eISSN - 2227-8575

pISSN - 2227-684X

DOI - 10.21037/gs-20-877

Subject(s) - medicine , pancreatic cancer , ca19 9 , oncology , cancer , chemotherapy , neoadjuvant therapy , adenocarcinoma , breast cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of malignant tumors with the worst prognosis. Surgery and adjuvant chemotherapy are the main treatments for resectable pancreatic cancer. For borderline resectable PDAC, neoadjuvant chemotherapy has been advised. For clearly resectable PDAC, neoadjuvant chemotherapy also might be considered for the patients with high-risk features, but with no precise quantitative criteria to define these features. So, this study aimed to re-evaluate the relationship between high-risk features and prognosis of clearly resectable pancreatic cancer, and to define the precise criteria for these high-risk features.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research